PLANS for rolling out weight-loss jab Mounjaro on the NHS are unambitious and reach a “woefully small number of people”, MPs have said.
Only around six per cent of eligible patients get or will receive Mounjaro on the in its first three years, with millions buying the GLP-1 drug privately.
The Commons Health and Social Care Committee said there is a two-tier system for access to the .
They added: “The Government must urgently reassess the pace of rollout of Mounjaro.”
It called for a summit of providers and healthcare professionals to decide the best way forward on access to GLP-1s.
In June 2024, the National Institute for Health and Care Excellence (Nice) recommended Mounjaro as an option for managing overweight and .
The NHS estimated 2.8million patients would be eligible for .
And if all were given the drug within the first year of availability, the cost would be £15.2billion over five years.
As a result, Nice agreed to a gradual rollout, MPs said.
The NHS has given access to 220,000 people over three years, but MPs say new “ambitious targets” are needed to help far more.
More than 2.37million packs of GLP-1s are prescribed every month in the UK, data suggests, with the vast majority being bought privately.
The MPs said people living with obesity are being let down by the NHS, with access determined by ability to pay rather than clinical need.
